Evaluating Emetine for Viral Outbreaks (EVOLVE) (EVOLVE)
Emetine for Viral Outbreaks: Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate Oral Emetine Against Covid-19 (EVOLVE)
Sponsor: Bharatpur Hospital Chitwan
Terminated
The study was terminated due to insufficient participant enrollment resulting from a lower-than-expected number of COVID-19 cases
A PHASE2/PHASE3 clinical study on COVID-19, this trial is terminated or withdrawn. The trial is conducted by Bharatpur Hospital Chitwan and has accumulated 11 data snapshots since 2024. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Recruiting → Terminated
-
Jun 2025 — Feb 2026 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 6 earlier versions
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Feb 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Aug 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bharatpur Hospital Chitwan
- Johns Hopkins University
- Nepal Health Research Council
- Rutgers University
- Stony Brook University
For direct contact, visit the study record on ClinicalTrials.gov .